Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
- 27 July 2011
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 130 (1), 345-351
- https://doi.org/10.1007/s10549-011-1686-9
Abstract
Metaplastic carcinoma of the breast (MCB) is a rare subtype of breast cancer. Anecdotal reports are available regarding its response to systemic chemotherapy. We reviewed the records of patients diagnosed with MCB at National Taiwan University Hospital between 1988 and 2009. A total of 46 MCB cases were identified from 8,695 breast tumor patients who underwent biopsy or resection. About 11 of 25 patients with initial bulky disease (T3-4) received neoadjuvant chemotherapy before surgery, and 2 (18.2%) exhibited a partial response. About 12 of 18 patients who developed distant metastasis received palliative systemic chemotherapy. Of them, only 1 (8.3%), 1 (10%), and none (0%) responded to first-, second-, or third- and beyond line chemotherapy, respectively. None of the patients who received anthracyline- (n = 13), vinorelbine- (n = 7), or cyclophosphamide-based (n = 18) chemotherapy responded, whereas 3 (17.6%) of 17 patients who received taxane-based chemotherapy exhibited a partial response. Tumor response to systemic chemotherapy remains generally poor for MCB patients. Taxanes may have modest activity, but need to be validated in further studies.Keywords
This publication has 18 references indexed in Scilit:
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI Journal of the National Cancer Institute, 2009
- Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data BaseAnnals of Surgical Oncology, 2006
- Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literatureBreast Cancer Research and Treatment, 2006
- Biphasic metaplastic sarcomatoid carcinoma of the breastAnnals of Oncology, 2006
- Metaplastic carcinoma of the breast Clinical presentation, treatment results and prognostic factorsActa Oncologica, 2006
- Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?Clinical Breast Cancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Metaplastic breast cancer: Prognosis and response to systemic therapyAnnals of Oncology, 1999
- Weekly Epirubicin Versus Doxorubicin as Second Line Therapy in Advanced Breast Cancer A Randomized Clinical TrialAmerican Journal of Clinical Oncology, 1991
- 5-Fluorouracil, Adriamycin, Cyclophosphamide (FAC) vs. 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Metastatic Breast CancerOncology, 1989